Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Betul Oran

Showing results (81-90 of 141) with videos related to

Pageof 15
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 5, 2010
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomasErica D Warlick, Marcie Tomblyn, Qing Cao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2020
Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical TrialUday Popat, Rohtesh S Mehta, Roland Bassett, et al.
Bone Marrow Transplantation|October 11, 2021
Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)Qaiser Bashir, Denái R Milton, Uday R Popat, et al.
Blood|August 15, 2022
Germ line predisposition variants occur in myelodysplastic syndrome patients of all agesSimone Feurstein, Amy M Trottier, Noel Estrada-Merly, et al.
American Journal of Hematology|February 5, 2024
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II studySairah Ahmed, Qaiser Bashir, Roland L Bassett, et al.
Transplantation and Cellular Therapy|November 27, 2022
Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice GuidelinesZachariah DeFilipp, Stefan O Ciurea, Corey Cutler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2013
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myelomaQaiser Bashir, Hassan Khan, Peter F Thall, et al.
Transplantation and Cellular Therapy|May 26, 2022
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study OutcomesGheath Alatrash, Chantal Saberian, Roland Bassett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2016
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study ResultsPartow Kebriaei, Roland Bassett, Genevieve Lyons, et al.
Transplantation and Cellular Therapy|December 5, 2022
HLA Factors versus Non-HLA Factors for Haploidentical Donor SelectionRohtesh S Mehta, Kai Cao, Rima M Saliba, et al.
Pageof 15

Showing results (81-90 of 141) with videos related to

Sort By:
Pageof 15
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 5, 2010
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomasErica D Warlick, Marcie Tomblyn, Qing Cao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2020
Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical TrialUday Popat, Rohtesh S Mehta, Roland Bassett, et al.
Bone Marrow Transplantation|October 11, 2021
Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)Qaiser Bashir, Denái R Milton, Uday R Popat, et al.
Blood|August 15, 2022
Germ line predisposition variants occur in myelodysplastic syndrome patients of all agesSimone Feurstein, Amy M Trottier, Noel Estrada-Merly, et al.
American Journal of Hematology|February 5, 2024
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II studySairah Ahmed, Qaiser Bashir, Roland L Bassett, et al.
Transplantation and Cellular Therapy|November 27, 2022
Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice GuidelinesZachariah DeFilipp, Stefan O Ciurea, Corey Cutler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2013
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myelomaQaiser Bashir, Hassan Khan, Peter F Thall, et al.
Transplantation and Cellular Therapy|May 26, 2022
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study OutcomesGheath Alatrash, Chantal Saberian, Roland Bassett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2016
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study ResultsPartow Kebriaei, Roland Bassett, Genevieve Lyons, et al.
Transplantation and Cellular Therapy|December 5, 2022
HLA Factors versus Non-HLA Factors for Haploidentical Donor SelectionRohtesh S Mehta, Kai Cao, Rima M Saliba, et al.
Pageof 15